Accéder au contenu
Merck

Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines.

The Journal of pharmacology and experimental therapeutics (2014-02-05)
Elisa Latorre, Ilaria Castiglioni, Pamela Gatto, Stephana Carelli, Alessandro Quattrone, Alessandro Provenzani
RÉSUMÉ

The protein kinase Cδ (PKCδ) interacts with and phosphorylates HuR, dictating its functionality. We show here that the genotoxic stimulus induced by doxorubicin triggers PKCδ interaction with HuR and leads to HuR phosphorylation on serines 221 and 318 and cytoplasmic translocation. This series of events is crucial to elicit the death pathway triggered by doxorubicin and is necessary to promote HuR function in post-transcriptional regulation of gene expression, because genetic ablation of PKCδ caused the inability of HuR to bind its target mRNAs, topoisomerase IIα (TOP2A) included. In in vitro select doxorubicin-resistant human breast cancer cell lines upregulating the multidrug resistance marker ABCG2, PKCδ, and HuR proteins were coordinately downregulated together with the doxorubicin target TOP2A protein whose mRNA was HuR-regulated. Therefore, we show here that PKCδ, HuR, and TOP2A constitute a network mediating doxorubicin efficacy in breast cancer cells. The importance of these molecular events in cancer therapy is suggested by their being profoundly suppressed in cells selected for doxorubicin resistance.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
DNA Gyrase from Escherichia coli, aqueous glycerol solution
Sigma-Aldrich
Topoisomerase II α human, (Single band on SDS-PAGE), liquid